SOCIO-ECONOMIC EFFECTIVENESS OF HEALTH SCREENING ACTIVITY IN 2013 IN RUSSIAN FEDERATION

Aim. To estimate long-term socio-economic effectiveness of broad health screening activity of adults by the results in the year 2013.

Material and methods. The study is performed with the method of mathematic modelling using the results of completed in the year 2013 health screening and with an estimate for adult productive and economically active age (up to 72) for 10-year perspective of potentially prevented deaths from the main chronic non-infectious diseases (CHID), saved years of life and economic expenses by 1 year of saved life.

Results. Through analyzed malignant tumours (MT) maximum deaths are to be prevented from breast cancer. The most significant effect of the performed screening is decrease of cardiovascular (CV) deaths — quantity of potentially saved lifes at productive age during 10 years would be 10 times higher than from MT. Screening for the studied CHID is characteristic for certain economic expediency, because expenses on 1 year of potentially saved life appeared lower than gross domestic product by one inhabitant. The most economic expediency of screening was found at the matter of CV diseases: expenses on 1 year of saved productve life (15,5^th RUR) and economically active age (11th RUR), that is significantly lower than domestic gross product by inhabitant. Return of investments into health improvement thank to earlier diagnostics of CHID and further treatment would reach 10 RUR per each invested 1 RUR by 10 years.

Conclusion. The analysis and calculations showed a significant positive effect of health screening in 2013, most of all due to earlier diagnostics and complex action against CV diseases and MT, which are included into screening and observation. Expenses on 1 year of saved life were lower than domestic gross product by inhabitant (in prices of the 2013) and return of investment by maintaining labour potential of economically active population was 10 RUR by 1 invested RUR during 10 years. Economic efficiency of health screening as a strategy to prevent premature death, preventable death and to keep health is clear.

1. Order of Ministry of Health of the Russian Federation from 03.12.12 № 1006n. Russian. (Приказ Министерства здравоохранения Российской Федерации от 03.12.2012 № 1006н) http://mpmo.ru/content/2013/01/Prikaz-№ 1006n-ot-03.12.2012-g..pdf

2. Order of the Ministry of Health of the Russian Federation from 06.12.12 № 1011n. Russian. (Приказ Министерства здравоохранения Российской Федерации от 06.12 2012 № 1011н) http://mzsrrf.consultant.ru/page.aspx?1029514

3. Strong K, Wald N, Miller, Alwan А. оn behalf of the WHO Consultation Group Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening. J Med Screen 2005 12: 12–9.

4. Wang P-E, Wang T-T, Chiu Y-H, et al. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions? J Med Screen 2006;13 (Suppl 1): S54–8.

5. Pharoah PD, Sewell B, Fitzsimmons D. Cost effectiveness of the NHS breast screening programme: life table model BMJ 2013; 346: f2618 doi: 10.1136/bmj.f2618

6. Tikhomirov AV, Yagudin RI. Pharmacoeconomic analysis of direct medical costs for the treatment of metastatic colorectal cancer in XELOX or FOLFOX4 mode in combination with or without bevacizumab as first-line therapy. Pharmacoeconomics. Modern Pharmacoepidemiology and Pharmacoeconomics 2010; 1: 22–7. Russian (Тихомирова А. В., Ягудина Р. И. Фармакоэкономический анализ прямых медицинских затрат при лечении метастатического колоректального рака в режиме XELOX или FOLFOX4 в сочетании с бевацизумабом или без него в качестве терапии первой линии. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология 2010; 1: 22–7).

7. Yagudinа RI, Zinchuk IY. Pharmacoeconomic analysis of the use of the drug Taxotere (docetaxel) in the treatment of breast cancer. Pharmacoeconomics 2013; 3: 31–5. Russian (Ягудина Р. И., Зинчук И. Ю. Фармакоэкономический анализ применения лекарственного средства Таксотер (доцетаксел) в лечении рака молочной железы. Фармакоэкономика 2013; 3: 31–5).

8. Derkach EV, Ignatieff VI, Shirokorad VI. Socio-economic burden of prostate cancer in the Russian Federation. Medical technology. Evaluation and selection in 2012; 2 (8): 34–45. Russian (Деркач Е. В., Игнатьева В. И., Широкорад В. И. Социально-экономическое бремя рака предстательной железы в Российской Федерации. Медицинские технологии. Оценка и выбор 2012; 2 (8): 34–45).

9. Oganov RG, Kontsevaya AV, Kalinina AM. The economic costs of cardiovascular diseases in the Russian Federation. Cardiovascular Therapy and Prevention 2011; 10 (4): 4–9. Russian (Оганов Р. Г., Концевая А. В., Калинина А. М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика 2011; 10 (4): 4–9).

10. Malignancies in Russia in 2012 (morbidity and mortality). Edited by Caprin AD, Starinskiy V, Petrova GV. Moscow 2014, 250p. Russian (Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под редакцией А. Д. Каприна, В. В. Старинского, Г. В. Петровой. Москва 2014, 250c).

11. Paci E. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screening 2012; 19 (Suppl 1): 5–13.

12. van Leeuwen PJ, Kranse R, Hakulinen T. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. J Med Screen March 2013; 20 (1): 33–8.

13. Massat N J, Moss SM, Halloran SP. Duffy S. W. Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences. J Med Screen 2013; 20: 125.

14. Kalinina AM. Scientific Evidence prevention of cardiovascular diseases in public health practice. Cardiovascular Therapy and Prevention 2010; 9 (1): 14–20.(Калинина А. М. Научные доказательные факты профилактики сердечно-сосудистых заболеваний в практическом здравоохранении. Кардиоваскулярная терапия и профилактика 2010; 9 (1): 14–20).

15. Kalinina AM, Kontsevaya AV, Deev AD. Long-term cost-effectiveness of prevention programs multifactorial cardiovascular disease in primary care. Cardiovascular Therapy and Prevention 2013; 1: 60–6. (Калинина А. М., Концевая А. В., Деев А. Д. Долгосрочная экономическая эффективность программы многофакторной профилактики сердечно-сосудистых заболеваний в первичной медико-санитарной помощи. Кардиоваскулярная терапия и профилактика 2013;1:60–6).